Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Medical Industry Feature

MAC Lung Disease: Considerations in Initiating Treatment

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

Tune in for an expert discussion on the progressive nature of untreated MAC lung disease as well as treatment options and management strategies recommended by the 2020 NTM Guidelines.

  • Sponsored by

  • Overview

    When Mycobacterium avium complex (MAC) lung disease is left untreated, there can be significant progression of disease,1 underscoring the importance of timely initiation of guideline-recommended management strategies.2 That’s why Drs. Nicole Lapinel and Wael ElMaraachli come together to discuss the progressive nature of untreated MAC lung disease, the available treatment options, and key management strategies. Dr. Lapinel is the Co-Director of the Adult Cystic Fibrosis Program and Clinical Assistant Professor of Medicine with Northwell Health in New York, and Dr. ElMaraachli is an Associate Clinical Professor and Director of the NTM Bronchiectasis Program at the University of California, San Diego.

    References:

    1. Gochi M, Takayanagi N, Kanauchi T, lshiguro T, Yanagisawa T, Sugita Y. Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease. BMJ Open. 2015;5(8):e008058. doi:10.1136/bmjopen-2015-008058
    2. Daley CL, laccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36. doi:10.1093/cid/ciaa241


    This program is brought to you by Insmed Incorporated.
    The consultants are paid speakers for Insmed.

    © 2024 Insmed Incorporated. All Rights Reserved.
    NP-NTM-US-00186 09/2024

Schedule9 Dec 2024